A longitudinal study of cognitive functioning in schizophrenia: Clinical and biological predictors

Schizophrenia Research

Volumn 156, Issue 2-3, 2014, Pages 248-253

  Dickerson, Faith ^a   Schroeder, Jennifer ^b   Stallings, Cassie ^a   Origoni, Andrea ^a   Katsafanas, Emily ^a   Schwienfurth, Lucy A B ^a   Savage, Christina L G ^a   Khushalani, Sunil ^a   Yolken, Robert ^c  

^a SHEPPARD PRATT HEALTH SYSTEM   (United States)

^b Schroeder Statistical Consulting   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cognitive; Longitudinal; Schizophrenia

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; C REACTIVE PROTEIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; LITHIUM SALT; OLANZAPINE; QUETIAPINE; RISPERIDONE; VIRUS ANTIBODY; ZIPRASIDONE; CATECHOL METHYLTRANSFERASE; COMT PROTEIN, HUMAN; LYMPHOTOXIN;

ADULT; AGED; ARTICLE; ATTENTION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEPTH PERCEPTION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENETIC POLYMORPHISM; HERPES SIMPLEX VIRUS 1; HUMAN; LANGUAGE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEMORY; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECALL; REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; BLOOD; GENETICS; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; PSYCHOSIS; STATISTICAL MODEL;

ADULT; ANTIBODIES, VIRAL; C-REACTIVE PROTEIN; CATECHOL O-METHYLTRANSFERASE; COGNITION; COGNITION DISORDERS; FEMALE; HERPESVIRUS 1, HUMAN; HUMANS; LINEAR MODELS; LONGITUDINAL STUDIES; LYMPHOTOXIN-ALPHA; MALE; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, GENETIC; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84901824905     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.04.019     Document Type: Article

References (38)

1. Bilder R.M., Lipschutz-Broch L., Reiter G., Geisler S.H., Mayerhoff D.I., Lieberman J.A. Intellectual deficits in first-episode schizophrenia: evidence for progressive deterioration. Schizophr. Bull. 1992, 18(3):437-448.
2. Bonner-Jackson A., Grossman L.S., Harrow M., Rosen C. Neurocognition in schizophrenia: a 20-year multi-follow-up of the course of processing speed and stored knowledge. Compr. Psychiatry 2010, 51(5):471-479.
3. Bora E., Murray R.M. Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis: do the cognitive deficits progress over, or after, the onset of psychosis?. Schizophr. Bull. 2013, (Jun 14, Epub ahead of print).
4. Dickerson F., Boronow J.J., Ringel N., Parente F. Social functioning and neurocognitive deficits in outpatients with schizophrenia: a 2-year follow-up. Schizophr. Res. 1999, 37(1):13-20.
5. Dickerson F.B., Boronow J.J., Stallings C., Origoni A.E., Ruslanova I., Yolken R.H. Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia. Arch. Gen. Psychiatry 2003, 60(5):466-472.
6. Dickerson F.B., Boronow J.J., Stallings C., Origoni A.E., Cole S., Leister F., Krivogorsky B., Yolken R.H. The catechol O-methyltransferase Val158Met polymorphism and herpes simplex virus type 1 infection are risk factors for cognitive impairment in bipolar disorder: additive gene-environmental effects in a complex human psychiatric disorder. Bipolar Disord. 2006, 8(2):124-132.
7. Dickerson F., Boronow J., Stallings C., Origoni A., Yolken R. The lymphotoxin Cys13Arg polymorphism and cognitive functioning in individuals with schizophrenia. Schizophr. Res. 2007, 89(1-3):173-176.
8. Dickerson F.B., Boronow J.J., Stallings C., Origoni A.E., Sullens A., Yolken R.H. The catechol O-methyltransferase Val158Met polymorphism is not associated with broad-based cognitive functioning in schizophrenia. Schizophr. Res. 2007, 96(1-3):87-92.
9. Dickerson F.B., Stallings C.R., Boronow J.J., Origoni A.E., Yolken R.H. A double-blind trial of adjunctive azithromycin in individuals with schizophrenia who are seropositive for Toxoplasma gondii. Schizophr. Res. 2009, 112(1-3):198-199.
10. Dickerson F.B., Stallings C.R., Origoni A.E., Sullens A., Khushalani S., Sandson N., Yolken R.H. A double-blind trial of adjunctive allopurinol for schizophrenia. Schizophr. Res. 2009, 109(1-3):66-69.
11. Dickerson F., Stallings C., Vaughan C., Origoni A., Goga J., Khushalani S., Yolken R. Artemisinin reduces the level of antibodies to gliadin in schizophrenia. Schizophr. Res. 2011, 129(2-3):196-200.
12. Dickerson F., Stallings C., Origoni A., Vaughan C., Khushalani S., Yolken R. Additive effects of elevated C-reactive protein and exposure to Herpes Simplex Virus type 1 on cognitive impairment in individuals with schizophrenia. Schizophr. Res. 2012, 134(1):83-88.
13. Dickinson D., Gold J.M., Dickerson F.B., Medoff D., Dixon L.B. Evidence of exacerbated cognitive deficits in schizophrenia patients with comorbid diabetes. Psychosomatics 2008, 49(2):123-131.
14. Fenton W.S., Dickerson F., Boronow J., Hibbeln J.R., Knable M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am. J. Psychiatry 2001, 158(12):2071-2074.
15. First M., Gibbon M., Spitzer R.L., Williams J.B.W. User's Guide for the SCID-I, Structured Clinical Interview for DSM IV Axis I Disorders 1996, Biometrics Research, New York, NY.
16. Friedman J.I., Harvey P.D., Kemether E., Byne W., Davis K.L. Cognitive and functional changes with aging in schizophrenia. Biol. Psychiatry 1999, 46(7):921-928.
17. Goldberg T.E., Keefe R.S., Goldman R.S., Robinson D.G., Harvey P.D. Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. Neuropsychopharmacology 2010, 35(5):1053-1062.
18. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry 1996, 153(3):321-330.
19. Harvey P.D., Silverman J.M., Mohs R.C., Parrella M., White L., Powchik P., Davidson M., Davis K.L. Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients. Biol. Psychiatry 1999, 45(1):32-40.
20. Heaton R.K., Gladsjo J.A., Palmer B.W., Kuck J., Marcotte T.D., Jeste D.V. Stability and course of neuropsychological deficits in schizophrenia. Arch. Gen. Psychiatry 2001, 58(1):24-32.
21. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998, 12(3):426-445.
22. Irani F., Kalkstein S., Moberg E.A., Moberg P.J. Neuropsychological performance in older patients with schizophrenia: a meta-analysis of cross-sectional and longitudinal studies. Schizophr. Bull. 2011, 37(6):1318-1326.
23. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
24. Klingberg S., Wittorf A., Sickinger S., Buchkremer G., Wiedemann G. Course of cognitive functioning during the stabilization phase of schizophrenia. J. Psychiatr. Res. 2008, 42(4):259-267.
25. Kurtz M.M. Neurocognitive impairment across the lifespan in schizophrenia: an update. Schizophr. Res. 2005, 74(1):15-26.
26. Leonard S., Mexal S., Freedman R. Smoking, genetics and schizophrenia: evidence for self medication. J. Dual Diagn. 2007, 3(3-4):43-59.
27. Meier M.H., Caspi A., Reichenberg A., Keefe R.S., Fisher H.L., Harrington H., Houts R., Poulton R., Moffitt T.E. Neuropsychological decline in schizophrenia from the premorbid to the postonset period: evidence from a population-representative longitudinal study. Am. J. Psychiatry 2014, 171(1):91-101.
28. Morisano D., Wing V.C., Sacco K.A., Arenovich T., George T.P. Effects of tobacco smoking on neuropsychological function in schizophrenia in comparison to other psychiatric disorders and non-psychiatric controls. Am. J. Addict. 2013, 22(1):46-53.
29. Napal O., Ojeda N., Sanchez P., Elizagarate E., Pena J., Ezcurra J., Gutierrez M. The course of the schizophrenia and its impact on cognition: a review of literature. Actas Esp. Psiquiatr. 2012, 40(4):198-220.
30. Nayak Savla G., Moore D.J., Roesch S.C., Heaton R.K., Jeste D.V., Palmer B.W. An evaluation of longitudinal neurocognitive performance among middle-aged and older schizophrenia patients: use of mixed-model analyses. Schizophr. Res. 2006, 83(2-3):215-223.
31. Rajji T.K., Voineskos A.N., Butters M.A., Miranda D., Arenovich T., Menon M., Ismail Z., Kern R.S., Mulsant B.H. Cognitive performance of individuals with schizophrenia across seven decades: a study using the MATRICS consensus cognitive battery. Am. J. Geriatr. Psychiatry 2013, 21(2):108-118.
32. Randolph C., Tierney M.C., Mohr E., Chase T.N. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J. Clin. Exp. Neuropsychol. 1998, 20(3):310-319.
33. Rodriguez-Sanchez J.M., Ayesa-Arriola R., Perez-Iglesias R., Perianez J.A., Martinez-Garcia O., Gomez-Ruiz E., Tabares-Seisdedos R., Crespo-Facorro B. Course of cognitive deficits in first episode of non-affective psychosis: a 3-year follow-up study. Schizophr. Res. 2013, 150(1):121-128.
34. Sponheim S.R., Jung R.E., Seidman L.J., Mesholam-Gately R.I., Manoach D.S., O'Leary D.S., Ho B.C., Andreasen N.C., Lauriello J., Schulz S.C. Cognitive deficits in recent-onset and chronic schizophrenia. J. Psychiatr. Res. 2010, 44(7):421-428.
35. Szoke A., Trandafir A., Dupont M.E., Meary A., Schurhoff F., Leboyer M. Longitudinal studies of cognition in schizophrenia: meta-analysis. Br. J. Psychiatry J. Ment. Sci. 2008, 192(4):248-257.
36. Wilk C.M., Gold J.M., Humber K., Dickerson F., Fenton W.S., Buchanan R.W. Brief cognitive assessment in schizophrenia: normative data for the Repeatable Battery for the Assessment of Neuropsychological Status. Schizophr. Res. 2004, 70(2-3):175-186.
37. Zhang X.Y., Chen da C., Xiu M.H., Haile C.N., Sun H., Lu L., Kosten T.A., Kosten T.R. Cigarette smoking and cognitive function in Chinese male schizophrenia: a case-control study. PLoS One 2012, 7(5):e36563.
38. Zipursky R.B., Reilly T.J., Murray R.M. The myth of schizophrenia as a progressive brain disease. Schizophr. Bull. 2013, 39(6):1363-1372.